Cipla receives USFDA nod for commonplace version of Revlimid

Cipla receives USFDA nod for commonplace version of Revlimid

by admin- Wednesday, September 7th, 2022 04:36:22 PM

Cipla received very last acclaim for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule five mg, 10 mg, 15 mg and 25 mg from the US Food and Drug Administration (USFDA).

Cipla’s Lenalidomide Capsules are AB-rated therapeutic equivalent typical model of Bristol Myers Squibb’s (Celgene) Revlimid (Lenalidomide) Capsules.

News Updates